OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer Presented ByProf. Hope Rugo, Helen Diller Family Comprehensive Cancer Centre, CA, USA TrialPhase 3, TROPiCS-02 ConferenceESMO 2022 TypePeer-reviewed article 16 November 2022 17:43